checkAd

     101  0 Kommentare Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 11:00 a.m. ET.

    The webcast of the presentation will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event.

    About Merus
    Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics. Multiclonics are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, X and LinkedIn.

    Multiclonics, Biclonics and Triclonics are registered trademarks of Merus N.V.

    CONTACT: Investor and Media Inquiries:
    Sherri Spear
    Merus N.V.
    VP Investor Relations and Corporate Communications
    617-821-3246
    s.spear@merus.nl
    
    Kathleen Farren
    Merus N.V.
    IR/Corp Comms
    617-230-4165
    k.farren@merus.nl




    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) - Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced …

    Schreibe Deinen Kommentar

    Disclaimer